43 filings
Page 2 of 3
6-K
u4c77t00ebj
30 Apr 21
Current report (foreign)
8:00am
6-K
lrk8vo52v
6 Apr 21
Stealth Biotherapeutics Reports Fiscal Year 2020 Financial Results and Recent Business Highlights
8:06am
6-K
uuqily4z9qg ev2o
11 Feb 21
Securities Purchase Agreement
8:04am
6-K
qvhd5c2x
7 Dec 20
Stealth BioTherapeutics Announces Appointment of Eve E. Slater, M.D., F.A.C.C. to its Board of Directors
4:20pm
6-K
oj4p6saln ij
23 Nov 20
Securities Purchase Agreement
4:05pm
6-K
af2h 7ctcgv
19 Nov 20
Current report (foreign)
5:16pm
6-K
fkuf8j9gc2 glvrl8
5 Nov 20
Stealth Biotherapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
8:06am
6-K
22060xr6y0je
4 Nov 20
6-K for Transaction
5:18pm
6-K
36jgr4h z9
7 Aug 20
Current report (foreign)
12:00am
6-K
uq8cm58fj3r3yshm
6 Aug 20
Stealth Biotherapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights
8:00am
6-K
1nboul um
3 Jun 20
Current report (foreign)
4:06pm
6-K
urjiul4t
7 May 20
Stealth Biotherapeutics Reports First Quarter 2020
8:20am
6-K
ihiq494fn 5c6
13 Apr 20
Stealth Biotherapeutics Announces $20 Million Financing to
8:38am
6-K
auact
3 Apr 20
Current report (foreign)
4:02pm
6-K
zn15gf1
16 Mar 20
Current report (foreign)
7:47am
6-K
jkjjvx3sdv gowv
7 Jan 20
Current report (foreign)
5:18pm
6-K
apxxid6n kxk
20 Dec 19
Stealth BioTherapeutics Provides Update on Phase 3 Trial of Elamipretide in Primary Mitochondrial Myopathy
5:09pm
6-K
itt7 vp7b8avdafb
14 Nov 19
Stealth Biotherapeutics Reports Third Quarter 2019
8:00am
6-K
vkp2kbrcrdrxp 8a0tu
10 Oct 19
Alexion and Stealth Announce Agreement for Option toCo-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
8:15am
6-K
ch6b66j
3 Sep 19
Stealth Biotherapeutics Announces Appointment of Robert
5:20pm